Patients with cardiovascular disease diagnosed with novel coronavirus (COVID-19) are urged to continue taking their angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) medications as prescribed.
Isolated diastolic hypertension, as defined in the 2017 ACC/AHA guideline was found to be more prevalent compared with IDH defined according to a 2003 recommendation.
Variability independent of the mean in SBP in young adults linked to CVD events, all-cause mortality.
In a population of elderly patients with hypertension, average blood pressure variability was found to decline during the 2 years following the initiation of antihypertensive medication.
Combination therapy consisting of once-daily macitentan and tadalafil was associated with reductions in pulmonary vascular resistance in patients with pulmonary arterial hypertension.
Broad support needed for providing BP refresher training for all roles of primary care health care providers.
Researchers conducted a systematic review and meta-analysis to identify the prevalence of hypertension in the general pediatric population.
For patients with type 2 diabetes, apparent treatment-resistant hypertension increases risk for cardiovascular events and mortality.
Complications such as preterm births and preeclampsia double the risk.
Women who experience hypertensive disorders during pregnancy are at an increased risk for cardiovascular disorders later in life.
